Bessemer Group
CRSP icon

Bessemer Group’s CRISPR Therapeutics CRSP Stock Holding History

Bessemer Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,538
Closed -$93K – 2042
2022
Q2 		$93K Hold
1,538
– – ﹤0.01% 1026
2022
Q1 		$97K Hold
1,538
– – ﹤0.01% 975
2021
Q4 		$117K Hold
1,538
– – ﹤0.01% 965
2021
Q3 		$172K Hold
1,538
– – ﹤0.01% 819
2021
Q2 		$249K Hold
1,538
– – ﹤0.01% 744
2021
Q1 		$187K Hold
1,538
– – ﹤0.01% 764
2020
Q4 		$235K Buy
+1,538
New +$182K ﹤0.01% 710
2020
Q3 		– Sell
-180
Closed -$13K – 1412
2020
Q2 		$13K Buy
+180
New +$10.5K ﹤0.01% 1501

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bessemer Group's CRSP Position: Q3 2022 in Review

Bessemer Group sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 1,538 shares — an estimated $93K sold.

Bessemer Group first reported a position in CRSP in Q2 2020 and held it in 8 quarters. The position peaked at $249K in Q2 2021. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

  • Bessemer Group reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bessemer Group sold 1,538 CRISPR Therapeutics shares in Q3 2022, an estimated $93K.
  • Bessemer Group first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 8 quarters.
  • Bessemer Group's CRISPR Therapeutics position peaked at $249K in Q2 2021.
  • 436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Bessemer Group's 13F filing for Q3 2022, filed 9 Nov 2022.